These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32694638)

  • 1. Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer.
    Raittinen P; Niemistö K; Pennanen E; Syvälä H; Auriola S; Riikonen J; Lehtimäki T; Ilmonen P; Murtola T
    Sci Rep; 2020 Jul; 10(1):12016. PubMed ID: 32694638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial.
    Raittinen PVH; Syvälä H; Tammela TLJ; Häkkinen MR; Ilmonen P; Auriola S; Murtola TJ
    EBioMedicine; 2021 Jun; 68():103432. PubMed ID: 34144486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.
    Murtola TJ; Syvälä H; Tolonen T; Helminen M; Riikonen J; Koskimäki J; Pakarainen T; Kaipia A; Isotalo T; Kujala P; Tammela TLJ
    Eur Urol; 2018 Dec; 74(6):697-701. PubMed ID: 30031572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access and concentrations of atorvastatin in the prostate in men with prostate cancer.
    Knuuttila E; Riikonen J; Syvälä H; Auriola S; Murtola TJ
    Prostate; 2019 Sep; 79(12):1412-1419. PubMed ID: 31231865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Preoperative Atorvastatin Treatment On Erectile Function After Radical Prostatectomy: Results From a Subgroup of ESTO1, a Randomized, Double-Blind, Placebo-Controlled Study.
    Siltari A; Riikonen J; Fode M; Murtola TJ
    J Sex Med; 2019 Oct; 16(10):1597-1605. PubMed ID: 31405764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
    Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
    Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Low-dose Statin Use after Radical Prostatectomy: The PRO-STAT Randomized Clinical Trial.
    Jeong IG; Lim B; Yun SC; Lim JH; Hong JH; Kim CS
    Clin Cancer Res; 2021 Sep; 27(18):5004-5011. PubMed ID: 34011557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol.
    Siltari A; Riikonen J; Koskimäki J; Pakarainen T; Ettala O; Boström P; Seikkula H; Kotsar A; Tammela T; Helminen M; Raittinen PV; Lehtimäki T; Fode M; Østergren P; Borre M; Rannikko A; Marttila T; Salonen A; Ronkainen H; Löffeler S; Murtola TJ
    BMJ Open; 2022 Apr; 12(4):e050264. PubMed ID: 35487730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
    Nicholls SJ; Ray KK; Ballantyne CM; Beacham LA; Miller DL; Ruotolo G; Nissen SE; Riesmeyer JS;
    Atherosclerosis; 2017 Jun; 261():12-18. PubMed ID: 28412650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
    Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
    JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
    Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
    Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
    Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
    Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial.
    Kulik A; Abreu AM; Boronat V; Ruel M
    J Thorac Cardiovasc Surg; 2019 Jan; 157(1):151-161.e1. PubMed ID: 30122341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
    Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
    Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial.
    Hari P; Khandelwal P; Satpathy A; Hari S; Thergaonkar R; Lakshmy R; Sinha A; Bagga A
    Pediatr Nephrol; 2018 Dec; 33(12):2299-2309. PubMed ID: 30091061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial.
    Tsujita K; Yamanaga K; Komura N; Sakamoto K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    Eur J Prev Cardiol; 2016 Sep; 23(14):1524-8. PubMed ID: 27296705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
    Atalar E; Ozmen F; Haznedaroglu I; Açil T; Ozer N; Ovünç K; Aksöyek S; Kes S
    Int J Cardiol; 2002 Aug; 84(2-3):227-31. PubMed ID: 12127376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Allott EH; Csizmadi I; Howard LE; Muller RL; Moreira DM; Andriole GL; Roehrborn CG; Freedland SJ
    BJU Int; 2020 Feb; 125(2):226-233. PubMed ID: 31479563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.